Indeed, the latter robustly express HER2 and tend to lose HR expression by the time mice are randomized to treatment or tumors are collected to generate cell lines [20–22], de facto modeling another type (HER2+) of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.